Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value Disclosures - Unobservable Level 3 inputs (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, Measurement input, Rate	0.131		0.131		0.131
Change in fair value of contingent consideration	$ 338	$ 68	$ 604	$ (428)
Percentage of increase in probability of success for Jade milestone			8.00%
Bayon \| Level 3 \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability of success for payment			17.00%		12.00%
Bayon \| Level 3 \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability of success for payment			67.00%		72.00%
Panoptes \| Level 3 \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability of success for payment			17.00%		17.00%
Panoptes \| Level 3 \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability of success for payment			36.00%		36.00%
Jade \| Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability of success for payment			55.00%		47.00%